Clinical and Molecular Hepatology

Previous issues

Volume 29(3) Jul 2023
Print ISSN: 2287-2728
Online ISSN: 2287-285X

Guidelines Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association: Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim; Clin Mol Hepatol. 2023;29(3):521-541.

KASL clinical practice guidelines for management of autoimmune hepatitis 2022: Clin Mol Hepatol. 2023;29(3):542-592.

Reviews Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity: Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi; Clin Mol Hepatol. 2023;29(3):593-604.

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection: Chih-Lin Lin, Jia-Horng Kao; Clin Mol Hepatol. 2023;29(3):605-622.

Acute hepatitis C virus infection: clinical update and remaining challenges: Chen-Hua Liu, Jia-Horng Kao; Clin Mol Hepatol. 2023;29(3):623-642.

A decade of liver organoids: Advances in disease modeling: Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan; Clin Mol Hepatol. 2023;29(3):643-669.

Acute-on-chronic liver failure: Terminology, mechanisms and management: Vinay Kumar BR, Shiv Kumar Sarin; Clin Mol Hepatol. 2023;29(3):670-689.

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis: Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen; Clin Mol Hepatol. 2023;29(3):705-720.

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma: Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo; Clin Mol Hepatol. 2023;29(3):721-732.

Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging: Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim; Clin Mol Hepatol. 2023;29(3):733-746.

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients: Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You; Clin Mol Hepatol. 2023;29(3):747-762.

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis: Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim; Clin Mol Hepatol. 2023;29(3):763-778.

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study: Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim; Clin Mol Hepatol. 2023;29(3):779-793.

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma: Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee; Clin Mol Hepatol. 2023;29(3):794-809.

Letters to the Editor Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”: Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han; Clin Mol Hepatol. 2023;29(3):810-811.

Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”: Halil Haldun Emiroglu; Clin Mol Hepatol. 2023;29(3):812-812.

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”: Hassam Ali; Clin Mol Hepatol. 2023;29(3):813-814.

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”: Amnuay Kleebayoon, Viroj Wiwanitkit; Clin Mol Hepatol. 2023;29(3):815-816.

Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”: Joo Hyun Oh, Dong Hyun Sinn; Clin Mol Hepatol. 2023;29(3):820-820.

Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”: Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng; Clin Mol Hepatol. 2023;29(3):821-822.

Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”: Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng; Clin Mol Hepatol. 2023;29(3):823-824.

Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]: Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong; Clin Mol Hepatol. 2023;29(3):830-830.